Vaxcyte (NASDAQ:PCVX) COO Jim Wassil Sells 3,477 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 3,477 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $61.07, for a total value of $212,340.39. Following the sale, the chief operating officer owned 155,041 shares in the company, valued at approximately $9,468,353.87. This represents a 2.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jim Wassil also recently made the following trade(s):

• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $53.86, for a total transaction of $121,185.00.
• On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.33, for a total transaction of $126,742.50.

Vaxcyte Trading Up 1.3%

Shares of PCVX opened at $61.58 on Thursday. The company’s fifty day simple moving average is $57.98 and its 200 day simple moving average is $56.12. Vaxcyte, Inc. has a 1-year low of $30.81 and a 1-year high of $65.00. The company has a market cap of $9.16 billion, a price-to-earnings ratio of -8.07 and a beta of 1.22.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09. During the same quarter last year, the firm posted ($1.22) earnings per share. As a group, research analysts forecast that Vaxcyte, Inc. will post -7.6 earnings per share for the current year.

Hedge Funds Weigh In On Vaxcyte

Several institutional investors and hedge funds have recently made changes to their positions in PCVX. Hsbc Holdings PLC lifted its holdings in Vaxcyte by 4.0% during the 2nd quarter. Hsbc Holdings PLC now owns 4,151 shares of the company’s stock worth $241,000 after purchasing an additional 159 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Vaxcyte by 33.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after buying an additional 184 shares in the last quarter. Meeder Advisory Services Inc. grew its holdings in Vaxcyte by 2.9% in the 1st quarter. Meeder Advisory Services Inc. now owns 8,335 shares of the company’s stock valued at $484,000 after buying an additional 231 shares in the last quarter. CWM LLC increased its position in Vaxcyte by 9.0% during the 4th quarter. CWM LLC now owns 2,840 shares of the company’s stock worth $131,000 after buying an additional 234 shares during the period. Finally, Northwestern Mutual Wealth Management Co. increased its position in Vaxcyte by 27.6% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,344 shares of the company’s stock worth $78,000 after buying an additional 291 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on PCVX shares. Zacks Research upgraded Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Wall Street Zen upgraded Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $86.00.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.